other material
confidence high
sentiment positive
materiality 0.90
VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial
Viking Therapeutics, Inc.
- Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).
- Up to 97% of VK2735 subjects achieved ≥5% weight loss vs 10% placebo; up to 80% achieved ≥10% vs 5% placebo.
- Safety: 99% of GI-related TEAEs mild/moderate; discontinuation due to AE in 20% VK2735 vs 13% placebo.
- Statistically significant weight loss seen in all doses >15 mg from Week 1 through Week 13.
- Exploratory maintenance arm: weight loss sustained after down-titration from 90 mg to 30 mg daily for 7 weeks.